Melanotan I vs Nonapeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Afamelanotide, Scenesse
Melanotan I is the research name for afamelanotide (code CUV1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. Sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), one of a few approved melanocortin drugs alongside bremelanotide (Vyleesi) and setmelanotide (Imcivree). The approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. The injectable 'Melanotan I' sold online is not approved for anything.
Also: Melanostatine 5, Melanostatine-5
Nonapeptide-1, sold as Melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-MSH, the hormone that tells pigment cells to make melanin. It goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. It is a cosmetic ingredient, not an FDA-approved drug, and there is no independent peer-reviewed clinical trial of it on its own.
Key Comparison Insights
- Melanotan I is FDA approved, while Nonapeptide-1 remains in research stages.
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Melanotan I has stronger research evidence (FDA Approved) compared to Nonapeptide-1 (Limited Research).
Detailed Comparison
| Attribute | Melanotan I | Nonapeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent. | When skin is hit by UV, it releases alpha-MSH, which binds the MC1R receptor on melanocytes and switches on tyrosinase, the enzyme that makes melanin. Nonapeptide-1 is designed to sit in that receptor without switching it on, a competitive antagonist, so less of the tanning and pigment signal gets through. In cell studies it binds MC1R with high affinity and blocks alpha-MSH-driven melanosome dispersion at nanomolar levels, and it lowered tyrosinase and related pigment genes in human melanocytes. It is essentially the opposite of melanotan I and afamelanotide, which activate the same receptor to darken skin. The big unknown, as with most cosmetic peptides, is how much reaches melanocytes through intact skin. |
| Common Dosing | 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) Daily during loading (1-2 weeks), then 1-2x weekly maintenance | Low percentage in a brightening serum Once or twice daily |
| Administration | Subcutaneous implant (not injection) | Topical (serums, creams) |
| Typical Duration | Long-term / as needed before sun season | Brightening claims are usually judged over 8 to 12 weeks; ongoing use |
| Best Time to Take | Before the sunny season (approved implant); evening for unapproved injectables | Morning (under sunscreen) and/or evening |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU (74) and US (94) who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (median 69.4 vs 40.8 hours in the US trial; 6.0 vs 0.8 hours in the EU trial, where phototoxic reactions also dropped from 146 to 77), and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. Clinuvel is also running a phase 3 vitiligo trial (CUV105), with topline results guided for December 2026. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane. | The evidence is thin and mostly commercial. Receptor binding and anti-pigment effects come from cell work and supplier data sheets. In a 2022 paper in Postepy Dermatologii i Alergologii (Chen and colleagues), nonapeptide-1 was used as a reference MC1R blocker in UVA-exposed human melanocytes and keratinocytes, where it reduced pigment pathway activity, but the study's focus was tea polyphenols, not the peptide. Ingredient databases describe the human data as small and manufacturer-generated. You will see claims online of a 12-week, 40-person trial where a cream with this peptide matched 4 percent hydroquinone for melasma, but we could not find a published, citable version, and even then it was a multi-ingredient cream. Fair summary: a well-designed molecule with a clear mechanism in cells, and very little real-world proof. Sunscreen still does more for dark spots than any single brightening peptide. |
Frequently Asked Questions: Melanotan I vs Nonapeptide-1
What is the difference between Melanotan I and Nonapeptide-1?
Melanotan I is a skin & hair peptide that melanotan i is the research name for afamelanotide (code cuv1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-msh), also written as [nle4, d-phe7]-alpha-msh or ndp-msh. sold as scenesse, it was approved by the ema in 2014 and the fda in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (epp), one of a few approved melanocortin drugs alongside bremelanotide (vyleesi) and setmelanotide (imcivree). the approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. the injectable 'melanotan i' sold online is not approved for anything. Nonapeptide-1 is a skin & hair peptide that nonapeptide-1, sold as melanostatine 5, is a nine-amino-acid synthetic peptide built to block alpha-msh, the hormone that tells pigment cells to make melanin. it goes into brightening and dark-spot products as a gentler alternative to harsh lighteners. it is a cosmetic ingredient, not an fda-approved drug, and there is no independent peer-reviewed clinical trial of it on its own. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Melanotan I or Nonapeptide-1?
Neither is universally "better" - the choice depends on your specific goals. Melanotan I is typically used for skin & hair purposes, while Nonapeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Melanotan I and Nonapeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Melanotan I and Nonapeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.